Crizotinib for the treatment of non-small-cell lung cancer

American Journal of Health-System Pharmacy

Volumn 70, Issue 11, 2013, Pages 943-947

  Timm, Andrew ^a   Kolesar, Jill M ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CARBOPLATIN; CRIZOTINIB; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOCETAXEL; KETOCONAZOLE; PEMETREXED; RIFAMPICIN; TESTOSTERONE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

APOPTOSIS; AREA UNDER THE CURVE; CELL PROLIFERATION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; GENE MUTATION; HUMAN; HYPOGONADISM; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NON SMALL CELL LUNG CANCER; PNEUMONIA; REVIEW; SIDE EFFECT; SURVIVAL RATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL DISORDER; VOMITING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COHORT ANALYSIS; LUNG NEOPLASMS; MORTALITY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRENDS;

CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84892716853     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120261     Document Type: Review

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62:10-29.
2. Azzoli CG, Baker S Jr, Temin S et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009; 27:6251-66.
3. National Comprehensive Cancer Network. NCCN guidelines v2.2013 NSCLC [registration required]. www.nccn.org/professionals/physician-gls/pdf/nscl.pdf (accessed 2013 Apr 1).
4. Xalkori (crizotinib) package insert. New York: Pfizer Labs.; 2011.
5. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448:561-7.
6. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12:175-80.
7. Husain H, Rudin CM. ALK-targeted therapy for lung cancer: ready for prime time. Oncology (Williston Park). 2011; 25:597-601.
8. Vysis ALK Break Apart FISH Probe Kit package insert. Des Plaines, IL: Abbott Molecular Inc.; 2011.
9. Choi YL, Takeuchi K, Soda M et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008; 68:4971-6.
10. Sasaki T, Okuda K, Zheng W et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010; 70:10038-43.
11. Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012; 18:1472-82.
12. Li C, Alvey C, Bello A et al. Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol. 2011; 29(suppl):abstract e13065.
13. ClinicalTrials.gov. A study to evaluate the pharmacokinetics of crizotinib (PF-02341066) in subjects with impaired renal function. http://clinicaltrials.gov/ct2/show/NCT01419041?term=crizotinib&rank=1 (accessed 2011 Nov 26).
14. ClinicalTrials.gov. Estimation of effect of ketoconazole on pharmacokinetics of crizotinib in healthy volunteers. http://clinicaltrials.gov/ct2/show/NCT01149785?term=crizotinib&rank=6 (accessed 2011 Dec 15).
15. ClinicalTrials.gov. Estimation of effect of rifampin on pharmacokinetics of crizotinib in healthy volunteers. http://clinicaltrials.gov/ct2/show/NCT01147055?term=crizotinib&rank=7 (accessed 2011 Dec 15).
16. Zhou WJ, Zhang X, Cheng C et al. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. Br J Pharmacol. 2012; 166:1669-83.
17. Kwak EL, Camidge DR, Clark J et al. Clinical activity observed in a phase I dose escalation trial of an oral c-MET and ALK inhibitor, PF-02341066. J Clin Oncol. 2009; 27(suppl 148s):abstract 3509.
18. Kwak E, Bang Y, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 28:1693-703.
19. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011; 12:1004-12.
20. Ou SH, Azada M, Dy J et al. Asymptomatic profound sinus bradycardia (heart rate d45) in non-small cell lung cancer patients treated with crizotinib. J Thorac Oncol. 2011; 6:2135-7.
21. Weickhardt AJ, Rothman MS, Salian-Mehta S et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012; 118:5302-9.
22. Ramalingam SS, Shaw AT. Hypogonadism related to crizotinib therapy: implications for patient care. Cancer. 2012; 118:E1-2.
23. ClinicalTrials.gov. An investigational drug, PF-02341066, is being studied versus standard of care in patients with advanced non-small cell lung cancer with a specific gene profile involving the anaplastic lymphoma kinase (ALK) gene. http://clinicaltrials.gov/ct2/show/NCT00932893?term=crizotinib&rank=16 (accessed 2011 Dec 22).
24. ClinicalTrials.gov. A clinical trial testing the efficacy of crizotinib versus standard chemotherapy pemetrexed plus cisplatin or carboplatin in patients with ALK positive non squamous cancer of the lung (PROFILE 1014). http://clinicaltrials.gov/ct2/show/NCT01154140?term=crizotinib&rank=20 (accessed 2011 Dec 22).
25. Ardini E, Magnaghi P, Orsini P et al. Anaplastic lymphoma kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy. Cancer Lett. 2010; 299(2):81-94.
26. Jung KT, Park BH, Hong BS. Progress in cancer targeting C-MET signaling pathway. Arch Pharm Res. 2012; 35:595-604.